Sino-US liver therapy developer AusperBio announced the successful closing of an oversubscribed Series B+ financing round, raising USD 50 million. The round was led by an existing, industry-leading venture capital investor, with participation from Qiming Venture Partners, CDH Investments, Genesis Capital, YuanBio Venture Capital, HanKang Capital, and Sherpa Capital.
Funding to Support Clinical Development and Expansion
The proceeds from the financing will be allocated to support the clinical development of AHB-137, a novel unconjugated antisense oligonucleotide therapy for chronic hepatitis B (CHB). This includes the planned Phase II trials outside mainland China. The funding will also facilitate the scale-up of commercial manufacturing partnerships and strengthen the company’s long-term pipeline growth.
AHB-137: A Promising Therapy for CHB
AHB-137 represents a innovative approach to treating chronic hepatitis B, leveraging antisense oligonucleotide technology to target the underlying mechanisms of the disease. The therapy has shown promising results in early-stage trials, highlighting its potential to address a significant unmet medical need in the treatment of CHB.-Fineline Info & Tech
